Prescription of antiretroviral and prophylactic drugs in HIV diseases: reality of medical practices
Bourdillon, F.; André, E.; Nadal, J.M.; Delfraissy, J.F.; Bez, G.
Annales de Medecine Interne 146(7): 500-504
1995
ISSN/ISBN: 0003-410X PMID: 8787292 Document Number: 448939
Antiretroviral and prophylactic therapy given to HIV-infected patients attending hospital (DMI 2 data base) was analyzed according to TCD4+ cell count; 19,020 patients were included in the study. Under 200 TCD4+/mm3, more than 80% of the patients received antiviral therapy, most often AZT (45.3%) or ddI (27.2%). Combined treatment was quite low, less than 8%. Although above 500 TCD4+/mm3, 11.6% of patients received AZT, this study showed that antiretroviral therapy followed French recommendations. This was not the case for prophylaxis: a large proportion of patients under 200 TCD4+/mm3 did not received pentamidine aerosol, or cotrimoxazole, or dapsone.